دورية أكاديمية
أعرض في EDS

Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis.

التفاصيل البيبلوغرافية
العنوان: Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis.
المؤلفون: Lv CB; From the Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China., Huang CM, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Chen QY, Cao LL, Lin M, Tu RH
المصدر: Medicine [Medicine (Baltimore)] 2016 May; Vol. 95 (21), pp. e3473.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Adenocarcinoma/*pathology , Esophagogastric Junction/*pathology , Lymph Node Excision/*methods , Stomach Neoplasms/*pathology, Aged ; Comorbidity ; Disease-Free Survival ; Female ; Gastrectomy ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Proportional Hazards Models ; Retrospective Studies ; Stomach Neoplasms/surgery ; Tumor Burden
مستخلص: The aim of the study is to identify the value of a spleen-preserving No. 10 lymphadenectomy (SPL) for Siewert type II/III adenocarcinoma of the esophagogastric junction (AEG).From January 2007 to June 2014, 694 patients undergoing radical total gastrectomy for Siewert type II/III AEG were analyzed. Oncologic outcomes were compared between SPL and no SPL (No. 10D+ and No. 10D-) groups.The incidence of No. 10 lymph node metastasis (LNM) was 12.3%. No significant differences in the incidence of No. 10 LNM were found between Siewert type II AEG with tumor diameters of <4 cm and ≥4 cm (P = 0.071). However, Siewert type III AEG with a tumor diameter ≥4 cm showed a significantly higher frequency of No. 10 LNM compared with a tumor diameter <4 cm (P < 0.001). The No. 10D+ group had superior 3-year overall survival (OS) and disease-free survival (DFS) rates compared with the No. 10D- group (P = 0.030 and P = 0.005, respectively). For patients with Siewert type II and type III AEG with a tumor diameter <4 cm, the 3-year OS and DFS rates were similar between the 2 groups. However, the No. 10D+ group had better 3-year OS (66.6% vs 51.1%, P = 0.019) and DFS (63.2% vs 45.9%, P = 0.007) rates for Siewert type III AEG with a tumor diameter ≥4 cm. A multivariate Cox regression showed that SPL was an independent prognostic factor in Siewert type III AEG with a tumor diameter ≥4 cm.SPL may improve the prognosis of Siewert type III AEG with a tumor diameter ≥4 cm, whereas SPL may be omitted without decreasing survival in patients with Siewert type II or type III AEG with a tumor diameter <4 cm.
References: Gastric Cancer. 2011 Jun;14(2):101-12. (PMID: 21573743)
Chin J Cancer Res. 2014 Jun;26(3):237-42. (PMID: 25035648)
Ann Surg Oncol. 2009 Dec;16(12):3237-44. (PMID: 19636628)
J Gastrointest Surg. 2009 May;13(5):881-5. (PMID: 19184612)
Recent Results Cancer Res. 2010;182:1-17. (PMID: 20676867)
J Gastrointest Surg. 2007 Aug;11(8):1039-44. (PMID: 17514409)
Ann Surg Oncol. 2008 Jul;15(7):1959-67. (PMID: 18369676)
Surg Today. 2012 Apr;42(4):351-8. (PMID: 22245924)
Ann Surg. 2004 Aug;240(2):205-13. (PMID: 15273542)
Br J Surg. 1995 Mar;82(3):346-51. (PMID: 7796005)
Br J Surg. 1998 Nov;85(11):1457-9. (PMID: 9823902)
Gastric Cancer. 2013 Oct;16(4):590-5. (PMID: 23179369)
Semin Radiat Oncol. 2013 Jan;23(1):3-9. (PMID: 23207041)
World J Surg Oncol. 2012 Nov 12;10:241. (PMID: 23146045)
J Surg Oncol. 2001 Feb;76(2):89-92. (PMID: 11223832)
Br J Surg. 2015 Mar;102(4):341-8. (PMID: 25605628)
Medicine (Baltimore). 2014 Nov;93(25):e158. (PMID: 25437029)
Gastric Cancer. 2014 Mar 22;:. (PMID: 24658651)
Chin J Cancer Res. 2014 Apr;26(2):208-10. (PMID: 24826062)
Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029)
Ann Surg Oncol. 2013 Dec;20(13):4252-9. (PMID: 23943020)
Ann Surg Oncol. 2012 Feb;19(2):677-83. (PMID: 21822549)
Gastric Cancer. 2012 Sep;15 Suppl 1:S89-99. (PMID: 21915699)
Gastric Cancer. 2013 Oct;16(4):454-6. (PMID: 23417699)
Ann Surg Oncol. 2009 May;16(5):1304-9. (PMID: 19241107)
Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1408-17. (PMID: 18374226)
تواريخ الأحداث: Date Created: 20160527 Date Completed: 20170213 Latest Revision: 20210109
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC4902337
DOI: 10.1097/MD.0000000000003473
PMID: 27227913
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000003473